Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Biofrontera (BFRI) over the last 4 years, with Sep 2025 value amounting to $3.4 million.

  • Biofrontera's Cash & Equivalents rose 17.83% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 17.83%. This contributed to the annual value of $5.9 million for FY2024, which is 339.69% up from last year.
  • According to the latest figures from Q3 2025, Biofrontera's Cash & Equivalents is $3.4 million, which was down 52.80% from $7.2 million recorded in Q2 2025.
  • Biofrontera's 5-year Cash & Equivalents high stood at $31.9 million for Q2 2022, and its period low was $1.3 million during Q1 2023.
  • In the last 3 years, Biofrontera's Cash & Equivalents had a median value of $3.4 million in 2023 and averaged $3.6 million.
  • As far as peak fluctuations go, Biofrontera's Cash & Equivalents skyrocketed by 1,503.61% in 2022, and later crashed by 94.20% in 2023.
  • Over the past 5 years, Biofrontera's Cash & Equivalents (Quarterly) stood at $24.5 million in 2021, then declined by 29.89% to $17.2 million in 2022, then plummeted by 92.20% to $1.3 million in 2023, then surged by 339.69% to $5.9 million in 2024, then increased by 17.83% to $3.4 million in 2025.
  • Its Cash & Equivalents stands at $3.4 million for Q3 2025, versus $7.2 million for Q2 2025 and $1.8 million for Q1 2025.